股票代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2023 - 001 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称及人员 线上参与公司2022年度业绩说明会的全体投资者 姓名 时间 2023年5月11日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/） 上市公司接待人员姓名 董事长、总裁 崔金海 董事会秘书、财务总监 郑晓程 独立董事 蔡曼莉 1.请问2022年外汇衍生品交易亏损2亿，针对这件事 能详细说明一下吗？另外，2023年会不会重蹈覆辙？ 投资者关系活动主要 答:尊敬的投资者您好！公司一般在财年开始针对全 年预计收入以及若干资产负债表项目预计金额进行衍生 内容介绍 品对冲。2022年外汇衍生品的亏损主要系因外汇汇率出 现单边行情，截止至2022年12月31日，美元汇率相较年 初汇率变动超9,600个基点，美元升值幅度达近16%，导 致公司衍生品出现较大亏损。公司目前海外收入占比仍较 高，且海外采购规 ...

奥美医疗用品股份有限公司 证券代码：002950 证券简称：奥美医疗 公告编号：2023-015 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 奥美医疗用品股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在巨 潮资讯网上披露了《奥美医疗用品股份有限公司 2022 年度报告全文》及《奥美 医疗用品股份有限公司 2022 年度报告摘要》。为便于广大投资者更加全面深入 地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 11 日（星期四） 会议召开时间：2023 年 05 月 11 日（星期四）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题征 集 ： 投资 者 可于 2023 年 05 月 11 日 前访 问 网 址 https://eseb.cn/14qQrEnnghG 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 ...

Financial Performance - The company's operating revenue for 2022 was ¥4,210,502,651.18, representing a 43.92% increase compared to ¥2,925,554,887.71 in 2021[31]. - The net profit attributable to shareholders for 2022 was ¥406,798,486.27, a decrease of 5.66% from ¥431,214,849.37 in the previous year[31]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 78.33% to ¥612,010,376.43 from ¥343,185,202.57 in 2021[31]. - The net cash flow from operating activities for 2022 was ¥1,149,727,552.87, a significant increase of 206.71% compared to ¥374,852,202.76 in 2021[31]. - The total assets at the end of 2022 were ¥5,747,507,000.10, reflecting a 14.84% increase from ¥5,004,829,011.10 at the end of 2021[31]. - The net assets attributable to shareholders at the end of 2022 were ¥3,101,070,727.75, up 12.65% from ¥2,752,953,286.33 in 2021[31]. - The basic earnings per share for 2022 were ¥0.6424, down 5.82% from ¥0.6821 in 2021[31]. - The diluted earnings per share for 2022 were also ¥0.6424, reflecting the same decrease of 5.82% from the previous year[31]. - The weighted average return on equity for 2022 was 14.09%, a decrease of 1.56% from 15.65% in 2021[31]. - The company reported a quarterly revenue of ¥1,143,341,270.23 in Q4 2022, with a net profit attributable to shareholders of ¥209,924,948.79 for the same quarter[35]. Revenue Sources and Market Trends - The company anticipates a potential decline in revenue from mask-related products in 2023, which may lead to fluctuations in overall revenue structure[11]. - The company's overseas operating revenue reached CNY 275,995.92 million, growing by 18.16% and accounting for 65.55% of total revenue[87]. - Domestic revenue surged by 145.98% to CNY 145,054.34 million, increasing its share of total revenue to 34.45%, up 14.29% from the previous year[89]. - The infection protection product line saw a remarkable increase in revenue of 190.82%, reaching ¥1,260,880,658.57, with a gross margin of 37.02%[96]. - The medical device segment generated ¥4,115,337,465.01, accounting for 97.74% of total revenue, with a year-on-year growth of 45.46%[94]. Risks and Challenges - The company faces risks related to foreign sales, which are heavily concentrated in developed markets like North America and Europe, potentially impacting overall performance due to external factors[7]. - Raw material costs, particularly for commodities like cotton, significantly affect the company's product costs and gross margins, with potential risks from price fluctuations[8]. - Exchange rate fluctuations pose a risk to sales revenue, as a substantial portion of sales is denominated in foreign currencies, which could impact pricing and operating income[9]. - The company utilizes derivative instruments to mitigate exchange rate risks, but significant fluctuations could still adversely affect gross margins and operating performance[10]. - The company emphasizes the importance of monitoring investment risks related to forward-looking statements in the annual report[6]. Research and Development - The company is focused on the research, development, production, and sales of medical consumables and disposable medical devices, indicating ongoing innovation in its product offerings[11]. - The company maintained a high level of R&D investment, with R&D expenses amounting to CNY 10,773.51 million, a 13.91% increase from the previous year[84]. - The company has invested significantly in research and development to improve product performance and meet regulatory requirements[55]. - The company is developing new high-end medical dressings, including silicone foam dressings and hydrogel dressings, to expand its market presence[106][108]. - The company has committed to increasing R&D investment in advanced dressing products, aiming to launch more upgraded products in the market[138]. Product Innovation and Market Position - The company has established a complete production process and quality management system, enhancing its competitiveness in the global market[46]. - The company is a leading player in the medical dressing industry in China, with strong competitive advantages and a focus on product innovation and quality improvement[54]. - The company has a comprehensive product line that includes surgical and wound care products, infection protection products, and advanced dressing products, catering to various medical needs[57]. - The company has developed a patented carboxymethyl polysaccharide technology, which is the first hydrophilic protonation technology platform in China, enhancing hemostatic capabilities and reducing blood loss[64]. - The advanced dressing products can absorb liquid up to 30 times their own weight, significantly improving healing and reducing the frequency of dressing changes[64]. Governance and Management - The board confirmed that all directors attended the meeting to review the annual report, ensuring accountability for the report's accuracy[5]. - The board of directors consists of 7 members, including 3 independent directors, meeting the requirement of one-third independence[147]. - The company has a supervisory board with 3 members, including one employee representative, ensuring effective supervision of financial and operational compliance[148]. - The company emphasizes stakeholder rights and social responsibility, aiming for balanced interests among shareholders, suppliers, customers, and employees[149]. - The company has established a robust investor relations framework, ensuring accurate and timely information disclosure since its listing on March 11, 2019[150]. Dividend and Shareholder Returns - The profit distribution plan approved by the board proposes a cash dividend of 0.60 CNY per 10 shares, based on a total share capital of 633,265,407 shares[13]. - The total number of shares for the dividend distribution was 633,265,407 shares, with a cash dividend payout ratio of 100% of the distributable profit[191]. - The cash dividend amount distributed accounted for 5.8% of the total distributable profit of RMB 653,483,299.39[191]. - The remaining undistributed profit will be carried forward to future distributions[191]. - There were no employee stock ownership plans or other employee incentive measures implemented during the reporting period[192].

Financial Performance - The company's operating revenue for Q1 2023 was ¥814,642,103.91, a decrease of 17.96% compared to ¥993,038,858.37 in the same period last year[5] - Net profit attributable to shareholders was ¥127,884,816.36, down 18.92% from ¥157,718,066.54 year-on-year[5] - Basic and diluted earnings per share were both ¥0.2019, representing an 18.95% decrease from ¥0.2491 in the same period last year[5] - Net profit for Q1 2023 was CNY 126,903,850.28, a decline of 20.1% from CNY 158,868,668.14 in Q1 2022[15] - Total operating revenue for Q1 2023 was CNY 814,642,103.91, a decrease of 18.0% compared to CNY 993,038,858.37 in the same period last year[14] Cash Flow - The net cash flow from operating activities was negative at -¥18,723,058.99, a decline of 105.66% compared to ¥330,956,749.48 in the previous year[5] - The net cash flow from operating activities for Q1 2023 was -18,723,058.99 CNY, a significant decrease compared to 330,956,749.48 CNY in the same period last year[16] - Total cash inflow from operating activities was 940,419,306.34 CNY, down from 1,202,779,163.11 CNY year-over-year[16] - Cash outflow from operating activities totaled 959,142,365.33 CNY, compared to 871,822,413.63 CNY in Q1 2022, indicating increased operational expenses[16] - The net cash flow from investing activities was -20,245,035.02 CNY, an improvement from -618,958,416.84 CNY in the previous year[16] - The net cash flow from financing activities was -181,235,250.55 CNY, a decline from 65,683,837.33 CNY in Q1 2022[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,408,683,142.95, down 5.90% from ¥5,747,507,000.10 at the end of the previous year[5] - Total liabilities for Q1 2023 were CNY 2,174,097,125.85, down from CNY 2,616,522,450.63 in the previous period[13] Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,810[9] - The largest shareholder, Cui Jinhai, holds 23.02% of the shares, followed by Cheng Hong with 15.14%[9] - Shareholders' equity attributable to the parent company increased by 3.37% to ¥3,205,653,161.46 from ¥3,101,070,727.75[5] - The total equity attributable to shareholders of the parent company was CNY 3,205,653,161.46, an increase from CNY 3,101,070,727.75 year-over-year[13] Expenses - Total operating costs for Q1 2023 were CNY 678,212,282.59, down 17.6% from CNY 822,936,104.86 year-over-year[14] - Research and development expenses for Q1 2023 were CNY 21,823,941.49, up 26.5% from CNY 17,272,408.39 in the same period last year[14] - The company reported a decrease in financial expenses, with a net financial cost of CNY -4,424,766.26 compared to CNY -99,815.56 in the previous year[14] - Other comprehensive income for Q1 2023 was CNY -23,302,382.65, compared to CNY -4,712,888.11 in the same period last year[15] Audit Status - The company’s first quarter report was not audited[18]

发布机构 证监会 发文日期 名 称 奥美医疗用品股份有限公司首次公开发行股票招股说明书（申报稿2017年11月14日报送） 文 号 主 题 词 | | | 奥美医疗用品股份有限公司首次公开发行股票招股说明书（申报稿 2017年11月14日报送） 根据《证券法》第二十一条和《首次公开发行股票并上市管理办法》第五十八条、《首次公开发行股票并在创业 板上市管理办法》第四十条的规定，申请文件受理后、发行审核委员会审核前，发行人应当将招股说明书（申报稿） 在中国证监会网站预先披露。 【打印】 【关闭窗口】 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-005 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|------------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 7 月 12 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事长 崔金海；董事、董事会秘书 杜先举；证券事务代表 | | 人员姓名 | 郑晓程。 | | | 投 资 者 关 系 活 | 1 | 、请公司介绍上半年业绩，比如说口罩类业务的 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-003 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|------------------------------|------------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 3 月 26 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事、副总裁兼董事会秘书 杜先举；证券事务代表 郑晓程 | | 人员姓名 | | | | 投 资 者 关 系 活 | 1. | 能否介绍下与国药器械签署合作的情况。 | | 动 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-004 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|-------------------------|----------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | √ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （电话会议） | | | 参 与 单 位 名 称 | 奥美医疗 2019 | 年度业绩网上说明会暨重大投资项目说明会 | | 及人员姓名 | 参会投资者 | | | 时间 | 2020 年 5 月 13 | 日 | | 地点 | 约调研、同花顺路演平台 | | | 上 市 公 司 接 待 | | 董事长及总裁崔金海，董事、副总裁兼董事会秘书杜先 | | 人员姓名 | | 举，董事、董事、副总裁兼财务总监黄文剑，独立董事蔡 | ...

证券代码：002950 证券简称：奥美医疗 编号：2020-001 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 天风证券 郑薇；景顺长城 姜雪婷；高毅资产 冯鹏；宝盈基 | | 人员姓名 | | 金 李进；大成基金 魏庆国；普渡资产 黄锐平；中庚基金 余 | | | | 思慧；云溪基金 程婷婷；康泰资产 陈璟；鹏华基金 郎超； | | | 通晟资产 张烨。 | | | 时间 | 2020 年 1 月 10 | 日下午 | | 地点 | | 深圳市奥美迪贸易发展有限 ...

证券代码：002950 证券简称：奥美医疗 编号：2020-002 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|-----------------------------|----------------------------------------------------| | | | | | 投 资 者 关 系 活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 （分析师电话会议） | | | 参 与 单 位 名 称 | 详见附件《参会机构名单》 | | | 及人员姓名 | | | | 时间 | 2020 年 2 月 9 日 | | | 地点 | 电话会议 | | | 上 市 公 司 接 待 | | 董事、董事会秘书 杜先举；证券事务代表 郑晓程 | | 人员姓名 | | | | 投 资 者 关 系 活 | 1. | 能否介绍下公司口罩的供应情况。 | | 动 主 要 内 容 ...